Last €13.08 EUR
Change Today -0.145 / -1.10%
Volume 0.0
As of 4:56 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Open
€13.10
Previous Close
€13.22
Day High
€13.10
Day Low
€13.08
52 Week High
01/23/15 - €13.45
52 Week Low
10/15/14 - €8.69
Market Cap
17.3B
Average Volume 10 Days
547.5
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products used to treat patients with atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to treat patients with peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat patients with non-vascular disease. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable pacemaker systems, including implantable cardiac resynchronization therapy pacemaker to treat heart failure; and medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides endoscopy products to treat diseases of the digestive and pulmonary systems; stone management products to treat patients with urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, Massachusetts.

23,000 Employees
Last Reported Date: 02/26/14
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $900.0K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $612.0K
Compensation as of Fiscal Year 2013.

boston scientific corp (BSX) Key Developments

Boston Scientific Wins Contract for Supply of 15 Subcutaneous Defibrillators

The San Carlos de Madrid hospital has hired Boston Scientific for the supply of 15 subcutaneous defibrillators, intended for the hospital's cardiovascular institute. The final value of the deal is EUR 328,000 (USD 387,000), VAT excluded.

Boston Scientific Corporation Announces Retiremnet of Pete M. Nicholas as Chairman of the Board of Directors

On December 30, 2014, Pete M. Nicholas, the Chairman of the Board of Directors of Boston Scientific Corporation, in order to facilitate an orderly transition of his responsibilities, notified the Board of Directors of the company that he expects to retire from the Board of Directors in 2017 and not stand for re-election at the annual meeting of the company's stockholders in 2017.

Boston Scientific Announces Favorable Data from Low Back Pain Study

Boston Scientific Corporation has announced that new retrospective data from a study evaluating the Precision Spectra Spinal Cord Stimulator, or SCS, System demonstrate that the device provided low back pain relief in 12 months after implantation. The outcomes review of 213 patients at 13 centers focuses on patients with chronic pain and chronic low back pain who are receiving treatment with the Precision Spectra SCS System. The system's Illumina 3D Software, an anatomy-driven computer model designed for simple point-and-click pain targeting, helps to address a key challenge in long term back pain relief: stimulating the neural target without stimulating undesired areas. At 12 months post-implantation, results include: Sustained and significant reduction in overall pain measured on the 0-10 numeric rating scale (NRS) was reported, from an average baseline score of 7.17, to an average score of 2.96 at 12 months post-implantation (N= 178); In patients with only low back pain (N= 73), a sustained and significant reduction of low back pain (measured on the 0-10 NRS scale) was reported, from an average baseline score of 7.21 to an average of 3.17 at 12 months post-implantation; and in patients with severe low back pain (N= 41, baseline score of 8 or greater measured on the 0-10 NRS scale), sustained and significant reduction in pain was reported, from an average score of 8.60 at baseline to 2.87 at 12 months post-implantation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:GR €13.08 EUR -0.145

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $143.40 USD -1.77
CR Bard Inc $178.20 USD -0.39
Olympus Corp ¥4,075 JPY -75.00
St Jude Medical Inc $64.99 USD -1.69
Terumo Corp ¥2,818 JPY +28.00
View Industry Companies
 

Industry Analysis

BSX

Industry Average

Valuation BSX Industry Range
Price/Earnings 69.2x
Price/Sales 2.7x
Price/Book 2.9x
Price/Cash Flow 27.3x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.